Richard E. Lowenthal - Nov 19, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Nov 19, 2024
Transactions value $
-$1,394,960
Form type
4
Date filed
11/21/2024, 04:30 PM
Previous filing
Nov 14, 2024
Next filing
Dec 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Sale -$698K -50K -3.58% $13.95 1.35M Nov 19, 2024 By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 F1, F2, F3
transaction SPRY Common Stock Sale -$697K -50K -4% $13.95 1.2M Nov 19, 2024 By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 F1, F4, F5
holding SPRY Common Stock 4.32M Nov 19, 2024 Direct
holding SPRY Common Stock 1.3M Nov 19, 2024 By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 F6
holding SPRY Common Stock 3.41M Nov 19, 2024 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
F2 The weighted average sale price for the transaction reported was $13.9502 and the range of prices were between $13.50 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 The weighted average sale price for the transaction reported was $13.949, and the range of prices were between $13.50 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
F6 The Reporting Person is trustee of the trust.